Kaiser Permanente agrees to Cxbladder EMR Integration

Company Announcement
1 JUNE 2022

KAISER PERMANENTE AGREES TO CXBLADDER EMR INTEGRATION

DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today announces
Kaiser Permanente, the largest integrated health provider in the US, has given the greenlight to
incorporate Cxbladder tests within its Electronic Medical Records (EMR) system.
The project, which is expected to take several months to complete, will mean clinicians across the Kaiser
Permanente Group will be able to order Cxbladder tests and view results directly within their clinical
workflow rather than relying on a manual ordering system. Additionally, patients will be able to provide
urine samples for Cxbladder tests at Kaiser Clinics and laboratories in addition to the current protocol of
relying on the Cxbladder Patient in Home Sampling System (PIHSS) initiated during COVID.
Pacific Edge Chief Executive Dr Peter Meintjes said: “Kaiser’s decision to include Cxbladder tests in its EMR
system represents an important commercial milestone for the group, offering a pathway to significantly
ease the administrative burden of ordering and recording the results of Cxbladder tests.
“As we noted when we announced our results for the year to 31 March 2022 last week, we have been
seeing steady growth in the volume of tests ordered by Kaiser clinicians with our clinic-by-clinic, clinician-
by-clinician rollout of Cxbladder. When the EMR integration is completed we expect to see an increased
rate of adoption of Cxbladder across Kaiser’s network of hospitals. Until the completion of the EMR
integration, we will continue to grow adoption on a structured clinic-by-clinic, clinician-by clinician basis,
initially with a focus on Southern California where Cxbladder was evaluated.”
Kaiser Permanente is one of the largest non-profit healthcare providers in the US, operating 39 hospitals,
734 offices and covering more than 12.6 million members, of which 85% are in California. The organization
is reported to manage around 2% of the urology patients in the US.
Pacific Edge has an agreement with the Kaiser Health Plan – the payor arm of Kaiser Permanente – to pay
for Cxbladder Triage and Cxbladder Monitor tests. The tests can assist clinicians to safely de-intensify
hematuria evaluation from low incidence populations and to reduce the frequency of surveillance
cystoscopy for recurrence of disease to improve patient compliance.
Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.
For more information:
Investors Media
Dr Peter Meintjes Richard Inder
Chief Executive The Project
Pacific Edge P: +64 21 645 643
P: +64 22 032 1263

Company Announcement
1 JUNE 2022

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and
commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of
recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through
its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

About Cxbladder www.cxbladder.com
Cxbladder is a non-invasive genomic urine test optimized for the detection and management of bladder cancer. The Cxbladder
evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications for primary detection,
surveillance, adjudication of atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous ongoing
and planned clinical studies to generate an ever-increasing body of clinical utility evidence supporting adoption and use in the
clinic to improve patient health outcomes. Cxbladder is reimbursed by CMS and has been trusted by over 2,000 US urologists
in the diagnosis and management of more than 80,000 patients, including the option for in-home sample collection. In New
Zealand, Cxbladder is accessible to 70% of the population via public healthcare and all residents have the option of buying the
test online.